Shimomura, Akihiko http://orcid.org/0000-0002-2557-8170
Nagahashi, Masayuki
Kumamaru, Hiraku
Aogi, Kenjiro
Asaga, Sota
Hayashi, Naoki
Iijima, Kotaro
Kadoya, Takayuki
Kojima, Yasuyuki
Kubo, Makoto
Miyashita, Minoru
Miyata, Hiroaki
Niikura, Naoki
Ogo, Etsuyo
Tamura, Kenji
Tanakura, Kenta
Yoshida, Masayuki
Yamamoto, Yutaka
Imoto, Shigeru
Jinno, Hiromitsu
Funding for this research was provided by:
Japan Society for the Promotion of Sciences (KAKENHI (JP19K16880))
Article History
Received: 24 March 2022
Accepted: 29 May 2022
First Online: 22 June 2022
Declarations
:
: Dr. Shimomura reports grants and personal fees from Chugai Pharmaceutical, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo, grants and personal fees from EISAI, grants from Taiho Pharmaceutical, grants from Mochida Pharmaceutical, personal fees from Pfizer, personal fees from Novartis, personal fees from Eli-Lilly, personal fees from Kyowa Kirin, personal fees from Takeda Pharmaceutical, and personal fees from MSD outside the submitted work. Dr. Kumamaru reports consulting fees from Mitsubishi-Tanabe Pharma, personal fees from Johnson and Johnson, personal feesl from Pfizer, personal fees from Chugai Pharmaceutical outside the submitted work, affiliated with the department of Healthcare Quality Assessment at the University of Tokyo supported by National Clinical Dabatase, Johnson & Johnson, and Nipro. Dr. Hayashi reports personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from EISAI, personal fees from Exact Science, personal fees from Eli-Lilly, personal fees from Daiichi Sankyo, personal fees from Novartis, personal fees from Pfizer, personal fees from Chugai Pharmaceutical outside the submitted work. Dr. Miyata reports grants from affiliation of social collaboration department of National Clinical Database, Johnson and Johnson, and Nipro. Dr. Yamamoto reports personal fees from AstraZeneca, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Kyowa Kirin, personal fees from Novartis, grants and personal fees from EISAI, grants and personal fees from Daiichi Sankyo, grants and personal fees from Nippon Kayaku, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Takeda, grants and personal fees from Eli-Lilly, grants and personal fees from Pfizer, personal fees from Taiho Pharmaceutical, personal fees from Sysmex, personal fees from MSD outside the submitted work. Dr. Imoto reports grants from Taiho Pharmaceutical, grants from Daiichi Sankyo, grants from Eli-Lilly outside the submitted work. The other authors declare no potential conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of the National Center for Global Health and Medicine, Tokyo (NCGM-G-003309-01) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.